Novo Holdings A S Buys 385,000 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Novo Holdings A S grew its stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 19.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,385,000 shares of the company’s stock after purchasing an additional 385,000 shares during the period. Viridian Therapeutics comprises about 2.7% of Novo Holdings A S’s investment portfolio, making the stock its 10th biggest position. Novo Holdings A S owned about 3.73% of Viridian Therapeutics worth $54,259,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of VRDN. Hennion & Walsh Asset Management Inc. grew its position in Viridian Therapeutics by 44.9% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 109,820 shares of the company’s stock worth $1,923,000 after purchasing an additional 34,040 shares during the last quarter. Principal Financial Group Inc. grew its position in Viridian Therapeutics by 9.7% in the 1st quarter. Principal Financial Group Inc. now owns 11,915 shares of the company’s stock worth $209,000 after purchasing an additional 1,058 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Viridian Therapeutics by 4.1% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,822 shares of the company’s stock worth $505,000 after acquiring an additional 1,135 shares during the period. Swiss National Bank increased its stake in Viridian Therapeutics by 23.4% in the first quarter. Swiss National Bank now owns 82,900 shares of the company’s stock valued at $1,452,000 after acquiring an additional 15,700 shares during the period. Finally, Vanguard Group Inc. increased its stake in Viridian Therapeutics by 7.8% in the first quarter. Vanguard Group Inc. now owns 3,234,279 shares of the company’s stock valued at $56,632,000 after acquiring an additional 233,331 shares during the period.

Viridian Therapeutics Price Performance

NASDAQ:VRDN opened at $23.05 on Friday. Viridian Therapeutics, Inc. has a 12 month low of $11.01 and a 12 month high of $25.39. The company’s 50-day moving average price is $20.22 and its two-hundred day moving average price is $16.11. The firm has a market cap of $1.47 billion, a PE ratio of -5.12 and a beta of 1.08. The company has a quick ratio of 15.82, a current ratio of 15.82 and a debt-to-equity ratio of 0.05.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Thursday, August 8th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.15). Viridian Therapeutics had a negative return on equity of 83.18% and a negative net margin of 79,185.77%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.09 million. On average, equities analysts anticipate that Viridian Therapeutics, Inc. will post -3.94 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $44.00 target price on shares of Viridian Therapeutics in a research note on Thursday, September 19th. Wedbush reissued an “outperform” rating and issued a $42.00 target price on shares of Viridian Therapeutics in a research note on Monday, July 29th. HC Wainwright reissued a “buy” rating and issued a $27.00 target price on shares of Viridian Therapeutics in a research note on Tuesday, September 10th. Needham & Company LLC upped their target price on shares of Viridian Therapeutics from $30.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Finally, The Goldman Sachs Group upped their target price on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $35.80.

Insider Transactions at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc bought 1,600,000 shares of Viridian Therapeutics stock in a transaction dated Friday, September 13th. The shares were bought at an average cost of $18.75 per share, for a total transaction of $30,000,000.00. Following the completion of the transaction, the director now owns 3,445,813 shares of the company’s stock, valued at approximately $64,608,993.75. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Viridian Therapeutics news, COO Thomas W. Beetham purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was acquired at an average cost of $23.41 per share, with a total value of $117,050.00. Following the completion of the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. This represents a 500.00 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fairmount Funds Management Llc purchased 1,600,000 shares of the company’s stock in a transaction that occurred on Friday, September 13th. The shares were acquired at an average cost of $18.75 per share, with a total value of $30,000,000.00. Following the completion of the purchase, the director now owns 3,445,813 shares of the company’s stock, valued at $64,608,993.75. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 1,626,400 shares of company stock worth $30,616,312. Corporate insiders own 0.65% of the company’s stock.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.